BioVie: Funding, Investors & Team (Sep 2026)
BioVie is leading the way in developing a new treatment for ascites caused by liver cirrhosis, a common complication of conditions such as NASH, alcoholic liver disease, and hepatitis C. Ascites, the build-up of fluid in the abdomen, is a major contributor to mortality for the approximately 100,000 Americans and many more worldwide who suffer from it. The company's drug, BIV201, is based on a medication currently approved in around 50 countries for treating similar liver cirrhosis-related complications. BioVie, formerly known as NanoAntibiotics, Inc., recently acquired LAT Pharma LLC, which brought the BIV201 development program under its umbrella. Following a meeting with the FDA in 2016 and now in the process of preparing its IND package, BioVie aims to start a US clinical trial as early as 2017.
BioVie has raised $24.0M across 2 funding rounds on record, the most recent an undisclosed round of $3.0M announced in Sep 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioVie Company Profile and Key Stats
Latest funding round on record: Sep 2024.
BioVie Funding Rounds
BioVie raised $21.0M in an undisclosed round announced in Mar 2024.
6 months later, an undisclosed round of $3.0M was announced in Sep 2024.
BioVie Founders and Leadership Team
No contact details are on record for this team yet.
BioVie Funding Compared to Other Biotechnology Startups
BioVie's latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioVie in Biotechnology and Beverly
Companies Similar to BioVie
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
BioVie Funding FAQs
What does BioVie do?
BioVie is leading the way in developing a new treatment for ascites caused by liver cirrhosis, a common complication of conditions such as NASH, alcoholic liver disease, and hepatitis C. Ascites, the build-up of fluid in the abdomen, is a major contributor to mortality for the approximately 100,000 Americans and many more worldwide who suffer from it. The company's drug, BIV201, is based on a medication currently approved in around 50 countries for treating similar liver cirrhosis-related complications. BioVie, formerly known as NanoAntibiotics, Inc., recently acquired LAT Pharma LLC, which brought the BIV201 development program under its umbrella. Following a meeting with the FDA in 2016 and now in the process of preparing its IND package, BioVie aims to start a US clinical trial as early as 2017.
How much funding has BioVie raised?
BioVie has raised $24.0M across 2 rounds on record. The most recent is an undisclosed round of $3.0M announced in Sep 2024.
When did BioVie last raise funding?
BioVie's most recent funding round on record is an undisclosed round of $3.0M, announced in Sep 2024.
Who founded BioVie?
FundedIQ lists O E Campbell (Founder) at BioVie.
Where is BioVie headquartered?
BioVie is based in Beverly, Massachusetts, United States.
How many employees does BioVie have?
BioVie is in the 11-50 employee band.
How does BioVie's funding compare to other Biotechnology startups?
BioVie's latest round of $3.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's BioVie Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioVie is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.